LAVA Sets Annual Shareholders Meeting for June 10, 2024

June 10, 2024 -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company specializing in the development of its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, has announced that the annual general meeting of shareholders is scheduled for Wednesday, June 19, 2024, at 2:00 pm CEST.

Details and documents pertinent to the annual general meeting, including the notice and agenda, can be found in the “Investors” section of LAVA’s website under “Annual Meeting.” These documents are also accessible on the SEC’s website. Shareholders interested in attending the meeting should register as specified in the notice and agenda.

About LAVA Therapeutics

LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology firm, focusing on the development of its proprietary Gammabody® platform. This platform aims to create a portfolio of bispecific gamma-delta T cell engagers intended for the potential treatment of both solid tumors and hematologic malignancies. The company's bispecific antibodies are engineered to selectively target and eliminate cancer cells by activating Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions through cross-linking to tumor-associated antigens.

Lead Program and Clinical Trials

LAVA's leading program, LAVA-1207, is presently under a Phase 1/2a dose escalation study (NCT05369000) aimed at evaluating its efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC). This study is actively enrolling participants across Europe and the United States and focuses on both monotherapy and combination therapy with interleukin-2 (IL-2).

Furthermore, LAVA is broadening the scope of its Phase 1/2a study to include a combination arm with KEYTRUDA® (pembrolizumab) via a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA. In addition to LAVA-1207, the company has licensed PF-08046052 (formerly LAVA-1223) to Pfizer Inc. for further clinical development and commercialization. Several pre-clinical programs are also part of LAVA's pipeline.

Patents and Trademarks

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. LLC, Rahway, NJ, USA. Gammabody® is a registered trademark of LAVA Therapeutics N.V.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!